Featured Clinical Trials
Aardvark is exploring the activity of ARD-101 in several settings in order to inform optimal designs for future studies. Initial clinical data demonstrate multiple strong signals of effect, and new studies are anticipated soon.
| Candidates | Indication | Preclinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|
| ARD-101 Oral | General Obesity | ||||
| Post-Bariatric Surgery | |||||
| Prader-Willi Syndrome | |||||
| ARD-380 Oral | Overactive Bladder | ||||
| ARD-501 Oral | Autism | ||||
| ARD-701 Topical | Inflammatory Skin Disorder | ||||
| ADT-101 Oral | Abuse Deterrence | ||||
| SP-104 Oral | Fibromyalgia | Partnered with Scilex Pharmaceuticals | |||
- ARD-101
Prader-Willi Syndrome
Status
Recruiting
NCT ID
NCT05153434
A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome
Stage: Phase 2
- ARD-101
Obesity
Status
Complete
NCT ID
NCT05121441
Study to Evaluate ARD-101 in Adults With Obesity
Stage: Phase 2
- ARD-101
Bariatric Surgery
Status
Recruiting
NCT ID
NCT05215847
Study to Evaluate ARD-101 in Adults Receiving Bariatric Surgery
